Neurology

A/Prof Jacqueline Anderson
Podcasts iconPodcasts

80% of people with mild traumatic brain injury will recover within 12 weeks

Dr Linda Calabresi
Clinical Articles iconClinical Articles

To understand the potential contribution of clinical neuropsychologists it is first necessary to understand what their scope of practice is and how this differs from clinical psychologists.

A/Prof Kelly Allott
Podcasts iconPodcasts

The mental health conditions most likely to present in young people

A/Prof Dana Wong
Podcasts iconPodcasts

Neuropsychologists specialise in evaluating conditions affecting the brain

Dr Marita Long
Podcasts iconPodcasts

The differences in dementia presentation between men and women and lifestyle modifications that may protect against dementia

Expert/s: Dr Marita Long
Dr Benjamin Tsang
Podcasts iconPodcasts

Recurrent vertigo, recurrent spontaneous vertigo, imbalance ataxia and persistent postural perceptual dizziness (PPPD)

Dr Benjamin Tsang
Podcasts iconPodcasts

Acute vestibular and acute transient vestibular syndromes and confirming the diagnosis of vestibular neuritis

Dr Benjamin Tsang
Podcasts iconPodcasts

The definition of vertigo and common misperceptions that doctors have

Dr Linda Calabresi
Clinical Articles iconClinical Articles

It’s all very well to tell a patient with Bell palsy – they haven’t had a stroke and they are likely to recover. When half their face appears paralysed such assurances aren’t all that comforting.

Sophie Scott
Clinical Articles iconClinical Articles

As our population continues to age, the number of people with dementia is set to skyrocket, a situation that geriatric medicine researcher A/Prof Michael Woodward has likened to a ‘tsunami that’s sadly almost bearing down on us’. Dementia already affects more than 400,000 Australians and is the second-biggest cause of death, but it’s predicted that this will grow to 589,000 by 2028 and more than one million by 2058. The debilitating condition causes a decline in memory, cognition and day-to-day functioning, a distressing process both for sufferers and their loved ones. Two new medications for dementia are currently being trialled, giving hope for more effective treatment. One is a monoclonal antibody gantenerumab, designed to remove the toxic protein amyloid from the brains of people with dementia. Although earlier trials have been disappointing, a higher dose is now being trialled in several thousand participants, including at Melbourne’s Austin Hospital.

Prof Malcolm Hopwood
Monographs iconMonographs

This article discusses a practical, evidence-based approach to the management of Major Depressive Disorder as it is likely to present in the real world setting.

Dr Vivienne Miller
Clinical Articles iconClinical Articles

General Practitioner Dr Vivienne Miller takes a look at what’s changed in the recently updated CHA2DS2-VASC Score for the determination of stroke risk factors from atrial fibrillation. The CHA2DS2-VA Score was updated from the CHA2DS2-VASC Score last year to exclude female sex (represented by Sc) in the determination of stroke risk factors from atrial fibrillation. The two scores are identical, apart from the exclusion of female sex, which is no longer considered an outright risk factor in stroke from atrial fibrillation, but more of a ‘risk modifier’ of this complication.1General Practitioner Dr Vivienne Miller takes a look at what’s changed in the recently updated CHA2DS2-VASC Score for the determination of stroke risk factors from atrial fibrillation. The CHA2DS2-VA Score was updated from the CHA2DS2-VASC Score last year to exclude female sex (represented by Sc) in the determination of stroke risk factors from atrial fibrillation. The two scores are identical, apart from the exclusion of female sex, which is no longer considered an outright risk factor in stroke from atrial fibrillation, but more of a ‘risk modifier’ of this complication.